LY 3023414

Drug Profile

LY 3023414

Alternative Names: LY3023414

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly; Sarah Cannon Research Institute
  • Developer Eli Lilly; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I Solid tumours
  • Phase Unknown Pancreatic cancer

Most Recent Events

  • 01 Dec 2016 Investigation in Pancreatic cancer in USA (PO) before December 2016
  • 01 Dec 2016 Eli Lilly plans a phase II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, United Kingdom, Argentina, Australia, Belgium, Brazil, France, Hungary, Israel, Spain and Taiwan (PO) (NCT02981342)
  • 07 Oct 2016 Adverse events data from a phase II trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top